Apogee Therapeutics (APGE) Non Operating Income (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Non Operating Income data on file, last reported at $8.7 million in Q1 2026.

• Non Operating Income for Q1 2026 came in at $8.7 million, up 11.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.9 million (down 15.25% YoY), and the FY2025 annual result was $30.0 million, down 13.56% from the prior year.
• Non Operating Income was little changed at $8.7 million in Q1 2026 per APGE's latest filing, from $8.7 million in the prior quarter.
• Over five years, Non Operating Income peaked at $10.3 million in Q2 2024 and troughed at -$9.2 million in Q3 2022.
• A 5-year average of $5.2 million and a median of $6.7 million in 2025 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2023 and 2025: Non Operating Income surged 5791.3% in 2023, then plunged 34.65% in 2025.
• A 5-year view of Non Operating Income shows it stood at $92000.0 in 2022, then surged by 5791.3% to $5.4 million in 2023, then surged by 60.17% to $8.7 million in 2024, then climbed by 0.58% to $8.7 million in 2025, then grew by 0.1% to $8.7 million in 2026.
• Business Quant data shows APGE's Non Operating Income at $8.7 million in Q1 2026, $8.7 million in Q4 2025, and $6.3 million in Q3 2025.